Pathogenetically determined approaches to the diagnosis and treatment of polyneuropathy

Authors

  • M.A. Trishchynska Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • O.E. Kononov Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2224-0713.16.8.2020.221956

Keywords:

polyneuropathy, history taking, antioxidants, microcirculatory disorders

Abstract

Distal symmetrical sensorimotor syndrome is quite common in clinical practice. It is very important to establish the cause of polyneuropathy in time and most accurately. There are about 100 causes of damage to the peripheral nervous system. Recently, increasing attention is paid to instrumental and laboratory research methods, while clinical diagnosis, careful history taking, careful examination can give more than 70 % of the diagnosis. It is very important not to stop searching for a possible etiological factor, even when at first glance the cause is obvious, but clinically there are discrepancies. In the process of finding the causative factors, it is important not to waste time and start treatment as early as possible. For this purpose, drugs can be used that are aimed at universal factors of pathogenesis — free radical oxidation, inflammation, edema, microcirculation disorders.

References

Abbott C.A., Malik R.A., van Ross E.R., Kulkarni J., Boulton A.J. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011. 34. 2220-4.

Akizuki S. A new method of hemostasis for cementless total knee arthroplasty. Bull. Hosp. Jt Dis. 1997. 56. 222-224.

Auteri A. Pharmacodynamics of troxerutin in patients with chronic venous insufficiency: correlation with plasma drug levels. Int. J. Clin. Pharmacol. Res. 1990. 10. 235-241.

Barohn R.J. Approach to peripheral neuropathy and neurono-pathy. Semin. Neurol. 1998. 18. 7-18.

Birklein F., Baron R., Gaul C. et al. Schmerz — ein vernachlässigtes neurologisches Thema. Nervenarzt. 2016. 87. 609-15.

Bromberg M.B., Smith A.G. Toward an efficient method to evaluate peripheral neuropathies. J. Clin. Neuromuscul. Dis. 2002. 3. 172-182

Burns T.M., Mauermann M.L. The Evaluation of Polyneuropathies. Neurology Clinical Practice. 2011. 76 (Suppl. 2). S6-S13. DOI 10.1212/WNL.0b013e31820c3622.

Sommer С., Geber C., Young Р., Forst R., Birklein F., Scho­ser В. Polyneuropathies Etiology, Diagnosis, and Treatment Options. Deutsches Ärzteblatt International. 2018. 115. 83-90.

Collins M.P., Hadden R.D. The nonsystemic vasculitic neuropathies. Nat. Rev. Neurol. 2017. 13. 302-16.

Dyck P.J., Lais A.C., Ohta M., Bastron J.A., Okazaki H., Groover R.V. Chronic inflammatory polyradiculoneuropathy. Mayo Clin. Proc. 1975. 50(11). 621-637.

England J.D., Asbury A.K. Peripheral neuropathy. Lancet. 2004. 363. 2151-2161.

England J.D., Gronseth G.S., Franklin G. et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review): report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neuro-logy. 2009. 72. 177-184.

Fan S. Troxerutin protects the mouse kidney from d-galactose-caused injury through anti-inflammation and anti-oxydation. Int. Immunopharmacol. 2009 Jan. 9(1). 91-6.

Finnerup N.B., Attal N., Haroutounian S. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015. 14. 162-73.

Gorson K.C., Ropper A.H. Additional causes for distal sensory polyneuropathy in diabetic patients. J. Neurol. Neurosurg. Psychiatry. 2006. 77. 354-358.

Azhary H., Farooq M.U., Bhanushali M., Majid А., Kassab M.Y. Peripheral Neuropathy: Differential Diagnosis and Management. American Family Physician. April 1, 2010. Vol. 81. № 7. S. 887-892.

Hughes R.A., Raphaël J.C., Swan A.V., van Doorn P.A. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst. Rev. 2001. (2). CD002063.

Hughes R.A. Peripheral neuropathy. BMJ. 2002. 324(7335). 466-469.

Lewis R.A. Chronic inflammatory demyelinating polyneuropathy. Neurol. Clin. 2007. 25(1). 71-87.

Lewis R.A. Toxic and deficiency neuropathies. Continuum Lifelong Learning Neurol. 2003. 9. 160-181.

Markvardsen L.H., Overgaard K., Heje K. et al. Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2018. 57. 70-6.

Martyn C.N., Hughes R.A. Epidemiology of peripheral neuropathy. J. Neurol. Neurosurg. Psychiatry. 1997. 62(4). 310-318.

Mauermann M.L., Burns T.M. The evaluation of chronic axonal polyneuropathies. Semin. Neurol. 2007. 28. 133-151.

McCarberg B.H., Billington R. Consequences of neuropathic pain: qualityof-life issues and associated costs. Am. J. Manag. Care. 2006. 12 (9 suppl.). S263-S268.

McQuay H., Carroll D., Jadad A.R., Wiffen P., Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ. 1995. 311 (7012). 1047-1052.

Ollat H., Cesaro P. Pharmacology of neuropathic pain. Clin. Neuropharmacol. 1995. 18(5). 391-404.

Pasnoor M., Dimachkie M.M., Barohn R.J. Cryptogenic sensory polyneuropathy. Neurol. Clin. 2013. 31. 463-76.

Raphaël J.C., Chevret S., Hughes R.A., Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst. Rev. 2001. (2). CD001798.

Rull J.A., Quibrera R., González-Millán H., Lozano Castañeda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia. 1969. 5(4). 215-218.

Sindrup S.H., Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999. 83(3). 389-400.

Sindrup S.H., Jensen T.S. Pharmacologic treatment of pain in polyneuropathy. Neurology. 2000. 55(7). 915-920.

Sommer C., Cruccu G. Topical treatment of peripheral neuropathic pain: applying the evidence. J. Pain Symptom. Manage. 2017. 53. 614-29.

Sommer C., Geber C., Young P., Forst R., Birklein F., Scho-ser B. Polyneuropathies — etiology, diagnosis, and treatment options. Dtsch Arztebl Int. 2018. 115. 83-90. DOI: 10.3238/arztebl.2018.083.

Sommer C., Üçeyler N. Small-Fiber-Neuropathien. Klin. Neurophysiol. 2017. 48. 63-72.

Stoltz J. Hemorrheology in clinical practice. Applications in an in vitro study of troxerutin. Rev. Fr. Gynecol. Obstet. 1991. 86. 200-205.

Treede R.D., Wagner T., Kern K.U. et al. Mechanism- and experiencebased strategies to optimize treatment response to the capsaicin 8 % cutaneous patch in patients with localized neuropathic pain. Curr. Med. Res. Opin. 2013. 29. 527-38.

Üçeyler N., Rogausch J.P., Toyka K.V., Sommer C. Differential expression of cytokines in painful and painless neuropathies. Neurology. 2007. 69. 42-9.

Willison H.J., Winer J.B. Clinical evaluation and investigation of neuropathy. J. Neurol. Neurosurg. Psychiatry. 2003. 74 (suppl. II). ii3-ii8.

Winer J.B. Guillain-Barré syndrome. BMJ. 2008. 337. a671.

Woolf C.J., Mannion R.J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999. 353(9168). 1959-1964.

Эрлих А.Д., Грацианский Н.А. Изучение доказательной базы использования препаратов, содержащих этилметилгидроксипиридина сукцинат, у пациентов с инсультом и его последствиями. Рациональная фармакотерапия в кардиологии. 2014. Т. 10. № 4. С. 448-456.

Published

2021-03-10

Issue

Section

Review